STUDIES ON HORMONAL TREATMENT FOR MASTOPATHY, PARTICULARLY ITS DOSE-RESPONSE RELATIONSHIP
スポンサーリンク
概要
- 論文の詳細を見る
The present studies were undertaken to ascertain a rational program of hormone administration for patients with mastopathy, in view of the fact that the dosage, mode, and duration of administration have varied widely in practice. The drug employed n the present studies was 2-alpha-methyl-dihydrotestosterone propionate (dromostanolone propionate). The drug recipients were divided into four groups according to dosage level: Group M-1 received 12.5 mg, group M-2, 25mg; group M-3, 50mg; and group M-4, 100mg; once per week. A control group (M-5) received 45mg of a depot-type testosterone once per week. The patients were assigned randomly to the groups by use of a table of random numbers. The drug was administered in double-blind fashion. The treatment produced no significantly different results with regard to spontaneous pain, tenderness, and softening of the tumor. However, regarding size the tumor diminution was proportionate to the level of dose. A similar tendency was observed in weight gain. Stratified analysis showed the tumor diminishing effect higher in the younger age group, in tumors larger in size, and in tumors poorly delineated. No age difference in the drug effect was observed in regard to weight gain. A rational administration of the present drug in patients with mastopathy seems to consist of the following: administration of 100mg once a week for 4 weeks; if the subsequent response is sufficient, treatment is halted, if the response is insufficient, the drug is continued for several weeks more in a reduced dose. If no response is elicited surgical managements are suggested.
- 社団法人 日本内分泌学会の論文
著者
-
IZUO Masaru
Department of Breast Surgery, Syorakudo Hospital
-
FUJIMORI MASAO
Department of Surgery, Gunma University School of Medicine
-
IZUO MASARU
Department of Surgery, Gunma University School of Medicine
関連論文
- Outcome of Breast-Conserving Therapy in the Tokyo Women's Medical University Breast Cancer Society Experience
- Decision Making Using Postoperative CEA and CA 15-3 for Detection of Breast Cancer Recurrence
- 2α, 3α-EPITHIO-5α-ANDROSTAN-17β-OI IN TREATMENT OF CHRONIC MASTOPATHY
- STUDIES ON HORMONAL TREATMENT FOR MASTOPATHY, PARTICULARLY ITS DOSE-RESPONSE RELATIONSHIP